- Home
- HEPS vs GHRS Comparison
HEPS vs GHRS Comparison
Compare HEPS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | GHRS |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Turkey | Ireland |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 947.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HEPS | GHRS |
|---|---|---|
| Price | $2.72 | $22.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $3.07 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 365.4K | 193.2K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $10.96 |
| 52 Week High | $3.30 | $24.66 |
Technical Indicators
Market Signals| Indicator | HEPS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 61.36 |
| Support Level | $2.52 | $12.65 |
| Resistance Level | $2.93 | $22.88 |
| Average True Range (ATR) | 0.10 | 1.49 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 57.91 | 58.59 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.